Novel anti-apoptotic MicroRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of Caspase 3, Caspase 9, and Bim

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Floyd, Desiree Hunt ^a   Zhang, Ying ^a   Dey, Bijan K ^a   Kefas, Benjamin ^a   Breit, Hannah ^a   Marks, Kaitlyn ^a   Dutta, Anindya ^a   Herold Mende, Christel ^b   Synowitz, Michael ^c   Glass, Rainer ^d   Abounader, Roger ^a   Purow, Benjamin W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 9; CD133 ANTIGEN; MICRORNA; MICRORNA 363; MICRORNA 582 5P; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; ONCOPROTEIN; PEPTIDE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROARRAY ANALYSIS; PHENOTYPE; PROTEIN EXPRESSION; REPORTER GENE; SITE DIRECTED MUTAGENESIS; STEM CELL; CANCER STEM CELL; CELL CULTURE; CYTOLOGY; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MEMBRANE PROTEINS; MICRORNAS; NEOPLASTIC STEM CELLS; PEPTIDES; PROTO-ONCOGENE PROTEINS;

EID: 84900522706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096239     Document Type: Article

References (77)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. CBTRUS (2010) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the US 2004-2006.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
4. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333. (Pubitemid 32524640)
5. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
6. Singh S and Dirks PB (2007) Brain tumor stem cells: identification and concepts. Neurosurg Clin N Am 18: 31-38, viii. (Pubitemid 46161197)
7. Vescovi AL, Galli R, Reynolds BA (2006) Brain tumour stem cells. Nat Rev Cancer 6: 425-436.
8. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021. (Pubitemid 39331011)
9. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, et al. (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39: 193-206.
10. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. (Pubitemid 37187480)
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401. (Pubitemid 39551674)
12. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760. (Pubitemid 44949604)
13. Quinones-Hinojosa A, Chaichana K (2007) The human subventricular zone: a source of new cells and a potential source of brain tumors. Exp Neurol 205: 313-324. (Pubitemid 46755774)
14. Angelastro JM, Lame MW (2010) Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 8: 1105-1115.
15. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015. (Pubitemid 46815044)
16. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, et al. (2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 18: 370-377. (Pubitemid 351782845)
17. Christensen K, Schroder HD, Kristensen BW (2010) CD133(+) niches and single cells in glioblastoma have different phenotypes. J Neurooncol.
18. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al. (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67.
19. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, et al. (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 94: 1-19.
20. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273. (Pubitemid 39382160)
21. Yan X, Ma L, Yi D, Yoon JG, Diercks A, et al. (2011) A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 108: 1591-1596.
22. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, et al. (2010) Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715-2728.
23. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, et al. (2010) Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133: 1961-1972.
24. Schmittgen TD (2008) Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med 12: 1811-1819.
25. Catania A, Maira F, Skarmoutsou E, D'Amico F, Abounader R, et al. (2011) Insight into the role of microRNAs in brain tumors (Review). Int J Oncol. 40: 605-624.
26. Godlewski J, Newton HB, Chiocca EA, Lawler SE (2009) MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ 17: 221-228.
27. Kim TM, Huang W, Park R, Park PJ, Johnson MD (2011) A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 71: 3387-3399.
28. Purow B (2010) The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J Neurooncol 103: 429-436.
29. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, et al. (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 23: 1327-1337.
30. Moore LM, Zhang W (2010) Targeting miR-21 in glioma: a small RNA with big potential. Expert Opin Ther Targets 14: 1247-1257.
31. Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, et al. (2010) Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 21: 303-314.
32. Shi L, Chen J, Yang J, Pan T, Zhang S, et al. (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352: 255-264.
33. Zhang J, Han L, Ge Y, Zhou X, Zhang A, et al. miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. (2010) Int J Oncol 36: 913-920.
34. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, et al. (2010) microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9: 1031-1036.
35. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, et al. (2010) Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol 12: 1102-1112.
36. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, et al. (2009) The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci 29: 15161-15168.
37. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is downregulated in glioblastoma. Cancer Res 68: 3566-3572.
38. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576.
39. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, et al. (2008) miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14.
40. Misawa A, Katayama R, Koike S, Tomida A, Watanabe T, et al. (2010) AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res 19: 23-33.
41. Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, et al. (2010) Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep 24: 195-201.
42. Lang MF, Yang S, Zhao C, Sun G, Murai K, et al. (2012) Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One 7: e36248.
43. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, et al. (2009) Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 15: 6541-6550.
44. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403. (Pubitemid 43668737)
45. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, et al. (2008) Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29: 918-925. (Pubitemid 351982234)
46. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH (2001) Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 29: 2549-2557. (Pubitemid 32600311)
47. Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, et al. (2011) MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer 18: 711-719.
48. Hao Y, Gu X, Zhao Y, Greene S, Sha W, et al. (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 4: 1073-1083.
49. Huang N, Lin J, Ruan J, Su N, Qing R, et al. (2012) MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett 586: 884-891.
50. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, et al. (2011) MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71: 5214-5224.
51. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, et al. (2010) MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 28: 1024-1030.
52. Galardi S, Mercatelli N, Farace MG, Ciafre SA (2011) NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res 39: 3892-3902.
53. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
54. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, et al. (2009) Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 20: 539-550.
55. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, et al. (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229.
56. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, et al. (2009) High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 15: 2089-2096.
57. Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, et al. (2010) Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 70: 3140-3149.
58. Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G, et al. (2009) MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 23: 4276-4287.
59. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
60. Weeraratne SD, Amani V, Neiss A, Teider N, Scott DK, et al. (2010) miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol 13: 165-175.
61. Butz H, Liko I, Czirjak S, Igaz P, Korbonits M, et al. (2011) MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary 14: 112-124.
62. Kumar P, Luo Y, Tudela C, Alexander JM, Mendelson CR (2013) The c-Myc-regulated microRNA-17∼92 (miR-17∼92) and miR-106a∼363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol 33: 1782-1796.
63. Landais S, Landry S, Legault P, Rassart E (2007) Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67: 5699-5707. (Pubitemid 46985002)
64. Dirks PB (2006) Cancer: stem cells and brain tumours. Nature 444: 687-688.
65. Dirks PB (2008) Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 363: 139-152.
66. Fabian MR, Sonenberg N, Filipowicz W (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
67. Ernst A, Campos B, Meier J, Devens F, Liesenberg F, et al. (2010) De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 29: 3411-3422.
68. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, et al. (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68: 9125-9130.
69. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, et al. (2003) Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via upregulation of BCL-2 family proteins. Blood 102: 87-93. (Pubitemid 36759640)
70. Wyllie AH (2010) "Where, O death, is thy sting?" A brief review of apoptosis biology. Mol Neurobiol 42: 4-9.
71. Hughes P, Bouillet P, Strasser A (2006) Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr Dir Autoimmun 9: 74-94.
72. Willis SN, Adams JM (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625. (Pubitemid 41540411)
73. Sabbagh L, Kaech SM, Bourbonniere M, Woo M, Cohen LY, et al. (2004) The selective increase in caspase-3 expression in effector but not memory T cells allows susceptibility to apoptosis. J Immunol 173: 5425-5433. (Pubitemid 39392126)
74. Camidge DR (2008) Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 8: 1167-1176.
75. Park KJ, Lee SH, Kim TI, Lee HW, Lee CH, et al. (2007) A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res 67: 7327-7334. (Pubitemid 47206562)
76. Zhu QY, Wang Z, Ji C, Cheng L, Yang YL, et al. (2011) C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis 2: e117.
77. Fuchs Y, Steller H (2011) Programmed cell death in animal development and disease. Cell 147: 742-758.